课题基金 / 基金详情

CARCINOEMBRYONAL ANTIGEN IDIOTYPE VACCINE

CARCINOEMBRYONAL ANTIGEN IDIOTYPE VACCINE
癌胚抗原独特型疫苗
批准号:
3493386
负责人:
HANS J HANSEN
金额:
$5.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-05-25 至 1993-11-24

项目摘要

项目成果

HANS J HANSEN的其他基金

相关文献

中文摘要
翻译
描述:(改编自申请者摘要)癌症患者 通常对肿瘤细胞上表达的抗原具有耐受性。 触发患者对肿瘤相关的主动免疫反应 抗原代表了癌症最有希望的前景之一。 心理治疗。在这个项目中,研究人员提出了一项临床前研究 触发主动免疫反应的抗独特型方法 对CEA的指控。某些抗独特型抗体针对 针对特定抗原的抗体的可变区可以模仿 (即,带有该抗原的内部图像)。在几个实验中 系统,用抗独特型抗体免疫可引起特异性 免疫代替原始抗原的免疫力。用抗-DNA免疫 独特型抗体作为替代抗原是一种很有前途的方法 触发对耐受抗原的免疫,如肿瘤抗原。他们有 已产生的狒狒多克隆和大鼠单克隆抗独特型抗体 抗原性模仿CEA的抗体。在这个项目中,他们将 评估这些抗独特型抗体是否可以作为替代品 仓鼠体内的抗原。仓鼠之所以被选中,是因为它们是唯一 已知的非免疫缺陷动物物种,在这些物种中人类产生CEA 肿瘤可能会生长。仓鼠代表了一种独特的模型来测试是否活跃 抗独特型免疫可防止肿瘤生长。这一阶段 我的研究将为更广泛的临床前和 第二阶段的临床研究。
英文摘要
DESCRIPTION: (Adapted from the applicant's abstract) Cancer patients are usually tolerant to the antigens expressed on tumor cells. Triggering an active immune response by the patients to tumor-associated antigens represents one of the most promising prospects in cancer therapy. In this project, the investigators propose a preclinical study of the anti-idiotype approach to trigger an active immune response against CEA. Certain anti-idiotypic antibodies directed against the variable regions of antibodies specific for a given antigen can mimic (i.e., bear the internal image of) this antigen. In several experimental systems, immunization with anti-idiotypic antibodies elicited specific immunity in lieu of the original antigen. Immunization with anti- idiotype antibodies as surrogate antigens is a promising approach to trigger immunity to tolerized antigens such as tumor antigens. They have already generated baboon polyclonal and rat monoclonal anti-idiotype antibodies that antigenically mimic CEA. In this project they will assess whether these anti-idiotype antibodies can function as surrogate antigens in hamsters. Hamsters have been chosen since they are the only known non-immunodeficient animal species in which human CEA-producing tumors may grow. Hamsters represent a unique model to test whether active anti-idiotype immunization can protect against tumor growth. This Phase I study will represent the basis for more extensive preclinical and clinical studies in Phase II.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RADIOIMMUNOTHERAPY USING BISPECIFIC ANTIBODIES
  • 批准号:
    6377254
  • 项目类别:
  • 资助金额:
    $25.4万
  • 财政年份:
    1999
  • 负责人:
    HANS J HANSEN
  • 依托单位:
RADIOIMMUNOTHERAPY USING BISPECIFIC ANTIBODIES
  • 批准号:
    6211887
  • 项目类别:
  • 资助金额:
    $44.29万
  • 财政年份:
    1999
  • 负责人:
    HANS J HANSEN
  • 依托单位: